Relay Therapeutics/$RLAY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
- Ticker
- $RLAY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 218
- Headquarters
- Cambridge, United States
- Website
- www.relaytx.com
RLAY Metrics
BasicAdvanced
$4B
-
-$1.51
1.74
-
Price and volume
Market cap
$4B
Beta
1.74
52-week high
$21.27
52-week low
$6.17
Average daily volume
2.6M
Financial strength
Current ratio
14.62
Quick ratio
14.346
Long term debt to equity
0.029
Total debt to equity
0.033
Profitability
EBITDA (TTM)
-318.546
Gross margin (TTM)
-2,583.30%
Net profit margin (TTM)
-2,837.03%
Operating margin (TTM)
-3,094.58%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-25.47%
Return on equity (TTM)
-41.16%
Valuation
Price to revenue (TTM)
338.954
Price to book
4.85
Price to tangible book (TTM)
4.88
Price to free cash flow (TTM)
-16.392
Free cash flow yield (TTM)
-6.10%
Free cash flow per share (TTM)
-1.104
Growth
Revenue change (TTM)
23.88%
Earnings per share change (TTM)
-13.45%
3-year revenue growth (CAGR)
-26.25%
3-year earnings per share growth (CAGR)
-17.33%
What the Analysts think about RLAY
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
Analyst projections of the future price of Relay Therapeutics stock.
Bulls say / Bears say
The FDA’s full approval of lirafugratinib, discovered on Relay’s platform, validates its drug-discovery approach and gives Relay potential milestone and royalty income through its Elevar deal. This is the first approved medicine to emerge from the platform. (Relay Therapeutics, U.S. Securities and Exchange Commission)
Early zovegalisib results in vascular anomalies look promising: 60% of the evaluable patients had a lesion-volume response at 12 weeks, and nearly all reported symptom improvement. Further follow-up is needed, but the findings suggest a potential second use for the drug beyond breast cancer. (Relay Therapeutics)
Relay ended Q3 with $848.6 million in cash and investments and expects funding into 2029. That gives it time to advance several clinical programmes without an immediate need to raise more capital. (Relay Therapeutics)
Zovegalisib’s breast-cancer evidence is still preliminary, while its Phase 3 trial must beat an active capivasertib comparator. Enrolment is not expected to finish until mid-2027, leaving a long wait for pivotal evidence. (Relay Therapeutics, Journal of Clinical Oncology)
Relay remains loss-making and has no product sales; its Q3 net loss was $81.7 million, and it expects significant expenses and losses for years. The stated cash runway helps, but the company says it will need additional financing in the future. (U.S. Securities and Exchange Commission)
Relay has licensed lirafugratinib’s global development and commercial rights to Elevar, so it will not capture direct sales from the newly approved drug. Its remaining upside depends on royalties and milestones, including up to $485 million in contingent payments. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
RLAY Financial Performance
Revenues and expenses
RLAY Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing RLAY
Fund name | Fund size | $RLAY weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.29% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.29% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.29% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.25% |
iShares Ageing Population£AGES | $887M | 0.25% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.